EyeGate Pharmaceuticals, Inc. (EYEG)

USD 35.56

(-0.73%)

Market Cap (In USD)

25.23 Million

Revenue (In USD)

12.05 Thousand

Net Income (In USD)

-8.09 Million

Avg. Volume

1132.00

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
35.5648-37.24
PE
-
EPS
-
Beta Value
0.797402
ISIN
US30233M5031
CUSIP
30233M503
CIK
1372514
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Stephen From
Employee Count
-
Website
http://www.eyegatepharma.com
Ipo Date
2015-02-13
Details
EyeGate Pharmaceuticals, Inc. is a clinical stage specialty pharmaceutical company, which engages in the development and commercialization of products for treating diseases and disorders of the eye. The company is headquartered in Waltham, Massachusetts and currently employs 11 full-time employees. The firm is focused on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye. The firm's lead product, EGP-437, incorporates a reformulated topically active corticosteroid, dexamethasone phosphate, which is delivered into the ocular tissues through its drug delivery system, the EyeGate II Delivery System. The firm is developing EGP-437 for the treatment of various inflammatory conditions of the eye, including uveitis, a debilitating form of intraocular inflammation of the anterior portion of the uvea, such as the iris and/or ciliary body, and macular edema, an abnormal thickening of the macula associated with the accumulation of excess fluids in the extracellular space of the neurosensory retina. The EyeGate II Delivery System is designed to deliver optimal quantities of drugs to the anterior or posterior segments of the eye.